Xpect Cold Relief Tablet
NDC Package 42961-112-14
Package Information
Xpect Cold Relief (acetaminophen guaifenesein phenylephrine hcl) tablets is • Adults and children 12 years of age and older: Take 2 tablets every 4 to 6 hours as needed. This formulation utilizes a tablet delivery system. Marketed by Cintas Corporation, this product is identified by NDC 42961-112 and is authorized under FDA application M013.
Identification & Billing
- RxCUI: 1243679 - acetaminophen 325 MG / guaiFENesin 200 MG / phenylephrine HCl 5 MG Oral Tablet
- RxCUI: 1243679 - acetaminophen 325 MG / guaifenesin 200 MG / phenylephrine hydrochloride 5 MG Oral Tablet
- RxCUI: 1243679 - APAP 325 MG / GG 200 MG / phenylephrine hydrochloride 5 MG Oral Tablet
- RxCUI: 1243679 - APAP 325 MG / Guaifenesin 200 MG / Phenylephrine Hydrochloride 5 MG Oral Tablet
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Decreased Respiratory Secretion Viscosity - [PE] (Physiologic Effect)
- Expectorant - [EPC] (Established Pharmacologic Class)
- Increased Respiratory Secretions - [PE] (Physiologic Effect)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 42961 - Cintas Corporation
- 42961-112 - Xpect Cold Relief
- 42961-112-14 - 40 PACKET in 1 BOX / 2 TABLET in 1 PACKET (42961-112-10)
- 42961-112 - Xpect Cold Relief
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (42961-112). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 42961-112-14 identifies a specific commercial package of 40 packet in 1 box / 2 tablet in 1 packet (42961-112-10) of Xpect Cold Relief, a human over the counter drug labeled by Cintas Corporation. This tablet is formulated for oral use and contains acetaminophen; guaifenesin; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cintas Corporation on March 29, 2021. The current certification is valid through December 31, 2027.
How is this Cintas Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 42961011214. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
